The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD).
The concept is that by delivering these particular microRNAs through EVs, Zofin will induce changes in cellular behavior that lessen disease-associated biological processes and, as such, diminish disease activity and ease symptoms.
Most notably, Zofin is believed to lessen inflammatory processes, which are involved in the progression of COPD and other respiratory diseases.
In addition to COPD, Zofin is being developed as a potential treatment for other conditions, including COVID-19. Three people with COVID-19 have already been treated with the investigational therapy, after emergency approval for these specific cases was granted by the FDA.
lAccording to Organicell, the clinical status of these patients improved, including their respiratory health.